Carisma Therapeutics, Inc. (CARM) has disclosed a new risk, in the Regulation category.
Carisma Therapeutics, Inc. faces substantial business risk due to its reliance on healthcare providers and third-party payors for drug recommendations and prescriptions post-marketing approval. The company’s arrangements with these parties are strictly regulated by anti-kickback, fraud, and abuse laws, including the Anti-Kickback Statute and the False Claims Act, at both federal and state levels, which could lead to severe legal and financial repercussions. Non-compliance could result in penalties, fines, and reputational damage, impacting Carisma Therapeutics’ profits and future earnings. Moreover, the complexity of these regulations, especially when considering international laws such as those in the EU, further complicates compliance and elevates the risk of inadvertent violations.
The average CARM stock price target is $10.00, implying 378.47% upside potential.
To learn more about Carisma Therapeutics, Inc.’s risk factors, click here.
